{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:24:37Z","timestamp":1787775877579,"version":"build-2784847793"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Purpose:<\/jats:title>\n                    <jats:p>The ability of autologous hematopoietic stem cell transplantation (ASCT) to improve the benefit of patients with high-risk diffuse large B-cell lymphoma (DLBCL) who achieved complete remission (CR) following induction chemotherapy is controversial. This multicenter real-world study aimed to explore the efficacy and safety of the rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen followed by consolidated ASCT therapy in newly diagnosed DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>From June 2018 to June 2021, the clinical data of patients with high-risk DLBCL who reached CR after receiving the R-CHOP regimen from ten lymphoma diagnosis and treatment centers were analyzed. Patients were included in the R-CHOP+ASCT (with consolidated ASCT therapy, n = 60) and R-CHOP (follow-up without consolidated ASCT therapy, n = 60) groups. The efficacy in the two groups was compared by difference analysis, and the safety of R-CHOP+ASCT was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Until June 2024, the median follow-up times for the R-CHOP+ASCT and R-CHOP groups were 44 (37.25\u201356) and 43.5 (38\u201352) months, respectively. Survivors were followed up for at least 36 months. In the R-CHOP+ASCT group, the 3-year disease-free survival (DFS) and overall survival (OS) rates were 89.7% and 96.7% and those in the R-CHOP group were 63.9% and 85.9%, respectively. The 3-year DFS rate in the R-CHOP+ASCT group was significantly higher than that in the R-CHOP group (89.7% vs 63.9%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001); no significant difference was found in the 3-year OS rate between the R-CHOP+ASCT and R-CHOP groups (96.7% vs 85.9%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.113). The 5-year DFS and OS rates in the R-CHOP+ASCT group were 73.6% and 77.6% and those in the R-CHOP group were 56.5% and 81.1%, respectively. The 5-year DFS rate in the R-CHOP+ASCT group was significantly higher than that in the R-CHOP group (73.6% vs 56.5%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009), whereas no significant difference was found in the 5-year OS rate between the R-CHOP+ASCT and R-CHOP groups (77.6% vs 81.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.246). In the Cox multifactorial analysis, discontinuous consolidated ASCT therapy, bone marrow invasion, and dual expression were poor prognostic factors that affect DFS [hazard ratio (HR), 5.710; 95% confidence interval (CI), 2.241\u201314.548,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; HR, 4.324; 95% CI, 1.890\u20139.893,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001; HR, 2.565; 95% CI, 1.145\u20135.747,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.022, respectively] and dual expression was a poor prognostic factor for OS (HR, 3.486; 95% CI, 1.300\u20139.344,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.013). Grade IV myelosuppression after transplantation developed in the R-CHOP+ASCT group, and other common grade 3 or 4 treatment-related adverse events were infection and fever.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>For patients with newly diagnosed high-risk DLBCL, consolidated ASCT therapy can increase the DFS rate of those with CR status following the R-CHOP regimen, and the safety is controllable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2102_24","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T02:04:20Z","timestamp":1746237860000},"page":"447-456","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Upfront autologous hematopoietic stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma: A real-world multicenter study"],"prefix":"10.4103","volume":"21","author":[{"given":"Zhi","family":"Guo","sequence":"first","affiliation":[{"name":"Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan, China"},{"name":"Department of Hematology, The 6Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Xian","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, National Cancer Center\/National Clinical Research Cancer for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Xiang","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hongkong University Shenzhen Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, National Cancer Center\/National Clinical Research Cancer for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, National Cancer Center\/National Clinical Research Cancer for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingye","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Clinical Research Center for Infectious Disease, Shenzhen Third People\u2019s Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shantou Central Hospital, Shantou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huizhou Central People Hospital, Huizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"R1-20250512","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.7150\/ijbs.67892","article-title":"Advances in multi-omics study of prognostic biomarkers of diffuse large B-cell lymphoma","volume":"18","author":"Liang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"R2-20250512","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cac2.12126","article-title":"Outcomes in refractory diffuse large B-cell lymphoma:Results from a multicenter real-world study in China","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"R3-20250512","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4103\/jcrt.jcrt_255_22","article-title":"The efficacy of PD-1 inhibitors in the maintenance treatment of diffuse large B-cell lymphoma:A single-center retrospective analysis","volume":"18","author":"Wei","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"R4-20250512","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","article-title":"New agents and regimens for diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R5-20250512","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER):A randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"key":"R6-20250512","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.17811","article-title":"Molecular profiling in diffuse large B-cell lymphoma:Why so many types of subtypes?","volume":"196","author":"Morin","year":"2022","journal-title":"Br J Haematol"},{"key":"R7-20250512","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"R8-20250512","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST:Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"key":"R9-20250512","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized Phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"R10-20250512","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-Adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma:Clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"R11-20250512","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cam4.3730","article-title":"R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients \u226560 years:Results of a randomized phase 2 study from the Spanish GELTAMO group","volume":"10","author":"Sancho","year":"2021","journal-title":"Cancer Med"},{"key":"R12-20250512","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/psp4.13141","article-title":"Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study","volume":"13","author":"Deng","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R13-20250512","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.2022017734","article-title":"Polatuzumab vedotin in previously untreated DLBCL:An Asia subpopulation analysis from the phase 3 POLARIX trial","volume":"141","author":"Song","year":"2023","journal-title":"Blood"},{"key":"R14-20250512","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3960\/jslrt.56.100","article-title":"Autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma","volume":"56","author":"Kondo","year":"2016","journal-title":"J Clin Exp Hematop"},{"key":"R15-20250512","doi-asserted-by":"crossref","first-page":"17808","DOI":"10.1002\/cam4.6412","article-title":"Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy:A retrospective study","volume":"12","author":"Yagi","year":"2023","journal-title":"Cancer Med"},{"key":"R16-20250512","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3960\/jslrt.23001","article-title":"Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma","volume":"63","author":"Haeno","year":"2023","journal-title":"J Clin Exp Hematop"},{"key":"R17-20250512","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-024-01085-9","article-title":"Hematopoietic stem cell transplantation for DLBCL:A report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years","volume":"14","author":"Berning","year":"2024","journal-title":"Blood Cancer J"},{"key":"R18-20250512","doi-asserted-by":"crossref","first-page":"17496","DOI":"10.1038\/s41598-023-44241-0","article-title":"The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed\/refractory diffuse large B cell lymphoma","volume":"13","author":"Min","year":"2023","journal-title":"Sci Rep"},{"key":"R19-20250512","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma:Final results of a randomized phase 2 study","volume":"130","author":"Casasnovas","year":"2017","journal-title":"Blood"},{"key":"R20-20250512","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jtct.2023.06.012","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma","volume":"29","author":"Epperla","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R21-20250512","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.17359","article-title":"Limited-stage diffuse large B-cell lymphoma:Current management and challenges","volume":"194","author":"Zhang","year":"2021","journal-title":"Br J Haematol"},{"key":"R22-20250512","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.hoc.2016.07.001","article-title":"Molecular classification of diffuse large B-cell lymphoma:What is clinically relevant?","volume":"30","author":"Sujobert","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"R23-20250512","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients:a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"R24-20250512","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/oncolo\/oyab004","article-title":"Translating the biology of diffuse large B-cell lymphoma into treatment","volume":"27","author":"Danilov","year":"2022","journal-title":"Oncologist"},{"key":"R25-20250512","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/cancers12010185","article-title":"Molecular complexity of diffuse large B-cell lymphoma:Can it be a roadmap for precision medicine?","volume":"12","author":"Coccaro","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R26-20250512","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41409-022-01767-7","article-title":"Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma","volume":"57","author":"Hanna","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R27-20250512","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/bjh.14100","article-title":"Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant:Subset analysis of randomized trial intergroup SWOG S9704","volume":"174","author":"Puvvada","year":"2016","journal-title":"Br J Haematol"},{"key":"R28-20250512","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s12185-016-1976-4","article-title":"Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma:A multicenter prospective phase II study (JSCT-NHL04)","volume":"103","author":"Murayama","year":"2016","journal-title":"Int J Hematol"},{"key":"R29-20250512","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S2352-3026(21)00022-3","article-title":"Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma:10-year follow-up of a randomised, open-label, phase 3 trial","volume":"8","author":"Frontzek","year":"2021","journal-title":"Lancet Haematol"},{"key":"R30-20250512","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1002\/cncr.32464","article-title":"Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era:A systematic review and meta-analysis","volume":"125","author":"Epperla","year":"2019","journal-title":"Cancer"},{"key":"R31-20250512","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N Engl J Med"},{"key":"R32-20250512","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.4081\/hr.2015.5812","article-title":"Favorable event free-survival of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for higher risk diffuse large B-cell lymphoma in first complete remission","volume":"7","author":"Kaneko","year":"2015","journal-title":"Hematol Rep"},{"key":"R33-20250512","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1002\/cnr2.1786","article-title":"The significance of upfront autologous stem cell transplantation for high-intermediate\/high-risk stage IV diffuse large B-cell lymphoma","volume":"6","author":"Koviazin","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"R34-20250512","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.4103\/jcrt.jcrt_33_24","article-title":"The role of fecal microbiota transplantation in the treatment of acute graft-versus-host disease","volume":"20","author":"Guo","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R35-20250512","doi-asserted-by":"crossref","first-page":"e15186","DOI":"10.1111\/ctr.15186","article-title":"Expert consensus on the relevance of intestinal microecology and hematopoietic stem cell transplantation","volume":"38","author":"Wang","year":"2024","journal-title":"Clin Transplant"},{"key":"R36-20250512","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.4103\/jcrt.jcrt_1444_22","article-title":"Chinese expert consensus on intestinal microecology and management of digestive tract complications related to tumor treatment (version 2022)","volume":"18","author":"Wang","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"R37-20250512","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/s41591-023-02587-y","article-title":"Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation","volume":"29","author":"Riwes","year":"2023","journal-title":"Nat Med"},{"key":"R38-20250512","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4103\/jcrt.jcrt_32_24","article-title":"Chinese guidelines for integrated diagnosis and treatment of intestinal microecology technologies in tumor application (2024 Edition)","volume":"20","author":"Wang","year":"2024","journal-title":"J Cancer Res Ther"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2102_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:44:57Z","timestamp":1787773497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2102_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2102_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-11-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}